NCT04792749 is a Phase 3 clinical trial of Metformin in Endometrial Cancer Stage I, sponsored by Samsung Medical Center.

Who is sponsoring NCT04792749?

NCT04792749 is sponsored by Samsung Medical Center.

What drugs are being tested in NCT04792749?

Interventions in NCT04792749: Metformin.

What condition does NCT04792749 study?

NCT04792749 studies Endometrial Cancer Stage I.

Is NCT04792749 still recruiting?

NCT04792749 is currently status unknown. Last updated 13 April 2023.

Last reviewed 2023-04-13 · How we verify

NCT04792749

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Effects of Metformin on Fertility-sparing Treatment for Early Endometrial Cancer

Status unknown Phase 3 Last updated 13 April 2023

What this trial tests

Phase 3 trial testing Metformin in Endometrial Cancer Stage I in 77 participants. Status unknown.

Timeline

1 June 2021

Primary endpoint
31 December 2023

31 March 2024

Quick facts

Lead sponsor	Samsung Medical Center
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	77
Start date	1 June 2021
Primary completion	31 December 2023
Estimated completion	31 March 2024
Sites	1 location across South Korea

Drugs / interventions tested

Metformin (metformin) — full drug profile →

Conditions studied

Endometrial Cancer Stage I — all drugs for Endometrial Cancer Stage I →

Sponsor

Samsung Medical Center

Who can join

Adults 18 to 45, female only, with Endometrial Cancer Stage I. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to investigate the effects of metformin in addition to the conventional progestin therapy in the fertility-sparing treatment of early stage endometrial cancer.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Endometrial Cancer in Reproductive Age: Fertility-Sparing Approach and Reproductive Outcomes.
Mutlu L, Manavella DD, Gullo G, McNamara B, et al · · 2022 · cited 61× · PMID 36358604 · DOI 10.3390/cancers14215187
Repurposing non-oncology small-molecule drugs to improve cancer therapy: Current situation and future directions.
Fu L, Jin W, Zhang J, Zhu L, et al · · 2022 · cited 47× · PMID 35256933 · DOI 10.1016/j.apsb.2021.09.006
Immunometabolism in cancer: basic mechanisms and new targeting strategy.
Su R, Shao Y, Huang M, Liu D, et al · · 2024 · cited 28× · PMID 38755125 · DOI 10.1038/s41420-024-02006-2
Progestin Resistance and Corresponding Management of Abnormal Endometrial Hyperplasia and Endometrial Carcinoma.
Lv M, Chen P, Bai M, Huang Y, et al · · 2022 · cited 17× · PMID 36551694 · DOI 10.3390/cancers14246210
Health position paper and redox perspectives - Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases.
Cuadrado A, Cazalla E, Bach A, Bathish B, et al · · 2025 · cited 9× · PMID 40059038 · DOI 10.1016/j.redox.2025.103569
The Interplay between Autophagy and Mitochondria in Cancer.
Zdanowicz A, Grosicka-Maciąg E. · · 2024 · cited 9× · PMID 39273093 · DOI 10.3390/ijms25179143
Levonorgestrel-releasing intrauterine device plus metformin, or megestrol acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial carcinoma: a prospective, randomized, blind-endpoint design trial protocol.
Zhao X, Niu J, Shi C, Liu Z. · · 2022 · cited 7× · PMID 36333773 · DOI 10.1186/s12978-022-01513-8

Verify or expand the search:

Other trials of Metformin

Trials testing the same drug.

NCT07275359 — Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations · Phase 1 · not yet recruiting
NCT07520110 — Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis · Phase 3 · not yet recruiting
NCT07007221 — Clinical Trials to Evaluate Metformin to Treat Depression in People Living With HIV · Phase 2 · not yet recruiting
NCT07585396 — Inositol in Letrozol Resistant PCOS Women · Phase 2, PHASE3 · not yet recruiting
NCT07226453 — Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Ependymoma · Phase 2 · not yet recruiting

Other recruiting trials for Endometrial Cancer Stage I

Currently open trials in the same condition.

NCT07040657 — Comparison of Two-Position and Four-Position Cervical Injection Techniques for Sentinel Lymph Node Mapping in Endometria · NA · recruiting
NCT06278857 — SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr) · Phase 2 · recruiting
NCT06417736 — Prospective Study for Endometrial Carcinoma and Hyperplasia in Childbearing-age Women · NA · recruiting
NCT05179447 — PROfiling Based Endometrial Cancer Adjuvant Therapy · NA · recruiting
NCT04839614 — Concurrent Laparoscopic Hysterectomy and Weight Loss Surgery in Obese Patients With Endometrial Carcinoma or Endometrial · NA · recruiting

Other Samsung Medical Center trials

Trials by the same sponsor.

NCT07482865 — Routine Versus Provisional Distal Perfusion Catheter Placement in Patients Undergoing Mechanical Circulatory Support · NA · not yet recruiting
NCT07467213 — Routine Use of Potassium Competitive Acid Blocker vs. Guideline-Directed Gastrointestinal Protection Strategy in Acute M · Phase 4 · not yet recruiting
NCT07530913 — Effectiveness Analysis of a Rehabilitation Exercise Platform for Living Donor Liver Transplantation Patients · NA · enrolling by invitation
NCT07500701 — Salvage Moderate Hypofractionated Versus Ultrahypofractionated Radiotherapy for Biochemical Recurrence After Radical Pro · Phase 3 · recruiting
NCT07409441 — Korea Acute Myocardial Infarction Registry · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04792749 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Samsung Medical Center
Last refreshed: 13 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04792749.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing